DAZZEON Biotech has initiated a significant partnership with Hoshi Pharmaceutical University in Japan this February 2024, focusing on the research of aloe polysaccharide DM1001 for treating gastric mucosal lesions. Given Japan’s consistently high rates of stomach cancer and the prevalence of gastric diseases, Hoshi Pharmaceutical University has shown keen interest in the potential of DM1001 for gastric mucosal repair.
This strategic collaboration aims to delve into the therapeutic potential of DM1001 against gastric diseases, particularly in combating stomach cancer. By working closely with Hoshi Pharmaceutical University, DAZZEON Biotech hopes to uncover the clinical efficacy and mechanisms of DM1001, offering new treatment avenues for stomach disease patients in Japan and worldwide. This partnership is expected to drive innovation in gastric disease treatment and foster further cooperation and exchange in biomedical research between the two parties.